Bioengineered skin allografts: A new method to prevent humoral response

ASAIO Journal

Volumn 57, Issue 3, 2011, Pages 239-243

  Brasile, Lauren ^a,b   Glowacki, Philip ^a   Stubenitsky, Bart M ^a,c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Breonics Inc   (United States)

^c St Antonius Academy   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTIFICIAL INTERFACES; B CELLS; BARRIER MEMBRANE; FIBROBLAST GROWTH FACTOR-1; IN-CONTROL; SKIN GRAFT; T CELL ACTIVATION; TARGETED DRUG DELIVERY; UNTREATED CONTROL;

ANTIBODIES; CELL CULTURE; DRUG DELIVERY;

GRAFTS;

FIBROBLAST GROWTH FACTOR 1; NANOMATERIAL; RECOMBINANT PROTEIN;

ALLOTRANSPLANTATION; ANIMAL; ARTICLE; ARTIFICIAL MEMBRANE; B LYMPHOCYTE; BAGG ALBINO MOUSE; BIOENGINEERING; C57BL MOUSE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; DRUG DELIVERY SYSTEM; DRUG EFFECT; ENDOTHELIUM CELL; EVALUATION; GRAFT REJECTION; HUMORAL IMMUNITY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MATERIALS TESTING; METHODOLOGY; MIXED LYMPHOCYTE CULTURE; MOUSE; SKIN TRANSPLANTATION;

ANIMALS; B-LYMPHOCYTES; BIOENGINEERING; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DRUG DELIVERY SYSTEMS; ENDOTHELIAL CELLS; FIBROBLAST GROWTH FACTOR 1; GRAFT REJECTION; IMMUNITY, HUMORAL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MATERIALS TESTING; MEMBRANES, ARTIFICIAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NANOSTRUCTURES; RECOMBINANT PROTEINS; SKIN TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 79955597238     PISSN: 10582916     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAT.0b013e3182155e52     Document Type: Article

References (22)

1. Brasile L, Glowacki P, Castracane J, Stubenitsky BM: Pretransplant kidney-specific treatment to eliminate the need for systemic immunosuppression. Transplantation 90:1294-1298, 2010.
2. Stubenitsky BM, Brasile L, Rebellato LM, et al: Delayed skin allograft rejection following matrix membrane pretreatment. J Plast Reconstr Aesthet Surg 62:520-525, 2009.
3. Product Technical Description. Wilmington, MA, Charles River Laboratories, 2006.
4. Sasamoto Y, Alexander JW, Babcock G: Prolonged survival of reconstituted skin grafts without immunosuppression. J Burn Care Rehabil 11:190-200, 1990. (Pubitemid 20301106)
5. Scuderi N, Mezzana P: The bioengineered organoid skin in plastic and reconstructive surgery, in Eisenmann-Klein M, Neuhann-Lorenz C (eds). Innovations in Plastic and Reconstructive Surgery, Berlin, Springer, 2008, pp. 24-28.
6. Kreis RW, Vloemans FPM, Hoeskstra MJ, et al: The use of nonviable glycerol-preserved cadaver skin combined with widely expanded autografts in the treatment of extensive third-degree burns. J Trauma 29:51-54, 1989. (Pubitemid 19054222)
7. Jacobson BK, Cuono CB, Kupper TS, Baker CC: Immunologic alterations following excisional wounding and immediate repair with syngeneic or allogeneic skin grafts. J Burn Care Rehabil 9:354-358, 1988.
8. Chen AM, Scott MD: Current and future applications of immunological attenuation via pegylation of cells and tissue. BioDrugs 15:833-847, 2001. (Pubitemid 33759681)
9. Armstrong JK, Meiselman HJ, Fisher TC: Covalent binding of poly (ethylene glycol) (PEG) to the surface of red blood cells inhibits aggregation and reduces low shear blood viscosity. Am J Hematol 56:26-28, 1997. (Pubitemid 27398054)
10. George KH: Stealthy blood cells manage to survive xenotransplantation. J NIH Res 6:26-28, 1997.
11. Scott MD, Murad KL: Cellular camouflage: Fooling the immune system with polymers. Curr Pharm des 4:423-438, 1998. (Pubitemid 28536750)
12. Jeong ST, Byun SM: Decreased agglutinability of methoxypolyethylene glycol attached red blood cells: Significance as a blood substitute. Artif Cells Blood Substit Immobil Biotechnol 24:503-511, 1996. (Pubitemid 26319155)
13. Scott MD, Murad KL, Koumpouras F, et al: Chemical camouflage of antigenic determinants: Stealth erythrocytes. Proc Natl Acad Sci USA 94:7566-7571, 1997. (Pubitemid 27345356)
14. Gundersen SI, Kennedy MS, Palmer AF: Immune recognition of exposed xenoantigens on the surface of PEGylated bovine red blood cells. Biotechnol Bioeng 101:337-344, 2008.
15. Jang JY, Lee DY, Park SJ, Byun Y: Immune reactions of lymphocytes and macrophages against PEG-grafted pancreatic islets. Biomaterials 25:3663-3669, 2004. (Pubitemid 38327055)
16. Tan Y, Qiu Y, Xu H, et al: Decreased immunorejection in unmatched blood transfusions by attachment of methoxypolyethylene glycol on human red blood cells and the effect on D antigen. Transfusion 46:2122-2127, 2006. (Pubitemid 44813730)
17. Beenken A, Mohammadi M: The FGF family: Biology, pathophysiology and therapy. Nat Rev Drug Discov 8:235-253, 2008.
18. Ornitz DM, Xu J, Colvin JS, et al: Receptor specificity of the fibroblast growth factor family. J Biol Chem 271:15292-15297, 1996. (Pubitemid 26195013)
19. Genot E, Petit-Koskas E, Sensenbrenner M, et al: Potentiation of the proliferative response of human B lymphocytes to low molecular weight B cell growth factor (LMW-BCGF) by fibroblast growth factors (FGFs). Cell Immunol 122:424-439, 1989. (Pubitemid 19232481)
20. Brisslent M, Bokarewa M, Larsson P, et al: Phenotypic and functional characterization of human CD25+ B cells. Immunology 117:548-557, 2006.
21. Amu S, Tarkowski A, Dorner T, et al: The human immunomoduatory CD25+ B cell population belongs to the memory B cel pool. Scand J Immunol 66:77-86, 2007. (Pubitemid 46985512)
22. Mittler R, Rao P, Olini G, et al: Activated human B cells display a functional IL 2 receptor. J Immunol 134:2393-2399, 1985. (Pubitemid 15105642)